此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Feasibility Trial of a Culturally Tailored Resilience Intervention for Underserved Breast Cancer Survivors (BRIGHT)

2026年11月5日 更新者:Sinem Uzar Ozcetin、University College Dublin

BRIGHT (Breast Cancer Resilience Intervention for Growth, Hope and Thriving): Co-Designing and Feasibility Testing a Culturally Tailored Resilience Intervention for Underserved Breast Cancer Survivors in Ireland

The goal of this feasibility trial is to find out whether a culturally tailored resilience intervention, called BRIGHT, can be delivered and tested with breast cancer survivors from underserved communities in Ireland. These include women from minority ethnic groups (including Travellers), migrant women, women living in rural areas and women experiencing socioeconomic disadvantage.

The main questions it aims to answer are:

  • Can enough women be recruited and kept in the study?
  • Do women attend the sessions and find the intervention acceptable?
  • Can facilitators deliver the intervention as planned? Researchers will compare the BRIGHT resilience intervention with usual survivorship care plus a resource booklet. The results will show whether a larger, definitive trial is possible and will give early signals of benefit for psychological distress, fear of cancer recurrence, resilience, quality of life and unmet supportive care needs.

Participants will:

  • Be randomly assigned to the BRIGHT resilience intervention or to usual care plus the BRIGHT Survivorship Resource Booklet
  • In the BRIGHT group, attend 8 weekly 90-minute facilitated group sessions, in the community or online
  • Complete questionnaires at the start, after 8 weeks and 3 months after the programme ends
  • Be invited to take part in an interview about their experience (some participants only) Women in the usual care group will be offered the BRIGHT programme after their final follow-up.

研究概览

详细说明

Background: Women from underserved communities in Ireland often experience higher psychological distress, fear of cancer recurrence, unmet supportive care needs and barriers to survivorship services. Few psychosocial survivorship interventions have been designed or culturally adapted for these groups.

Intervention development: The BRIGHT resilience intervention is being developed in earlier stages of Project BRIGHT, a 42-month mixed methods study submitted for funding to Breast Cancer Now. These stages include a national survey of breast cancer survivors, interviews with women from underserved communities and a structured co-design process with survivors, clinicians, researchers and community stakeholders. Cultural adaptation is guided by Resnicow's Cultural Adaptation Framework and documented using FRAME.

Intervention: An 8-week hybrid programme of weekly 90-minute facilitated group sessions, delivered face to face in the community and through secure online sessions, with a participant workbook. Planned modules, subject to the co-design findings, are psychoeducation; emotional adjustment; managing fear of recurrence; culturally responsive coping and resilience; self-advocacy; healthcare navigation; peer support; and signposting to community resources. Materials will be translated into 2 to 3 priority languages.

Design: A two-arm parallel feasibility randomised controlled trial with 80 participants, individually randomised 1:1. A computer-generated, concealed allocation sequence will be managed by an independent researcher not involved in recruitment or intervention delivery. The comparator is usual survivorship care plus the BRIGHT Survivorship Resource Booklet, with delayed access to the BRIGHT programme after the 3-month follow-up (waitlist crossover). Allowing for up to 25% attrition, at least 60 participants are expected to be evaluable at final follow-up.

Data collection: Questionnaires at baseline (T0), after the intervention (T1, Week 8) and 3 months after the intervention (T2).

Progression criteria: Progression to a definitive trial will be guided by pre-specified traffic light criteria: at least 80% retention, at least 75% session completion, at least 85% intervention fidelity and a recruitment rate of at least 4 participants per site per month.

Process evaluation: Guided by the MRC Process Evaluation Framework, semi-structured interviews with 15 to 20 participants and facilitators will explore acceptability, barriers and facilitators to implementation, mechanisms of impact, fidelity and context. Fidelity will be assessed using facilitator session checklists, attendance records and independent review of a sample of recorded sessions.

Analysis: Feasibility outcomes will be reported using descriptive statistics with 95% confidence intervals. Exploratory analyses of secondary outcomes will estimate effect sizes and variance to inform the sample size for a future definitive trial.

研究类型

介入性

注册 (估计的)

80

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

女性

描述

Inclusion Criteria:

  • Women aged 18 years or older.
  • Diagnosis of breast cancer stage 0 to III.
  • Completed primary treatment (surgery, chemotherapy and/or radiotherapy)
  • Belong to at least one underserved group: minority ethnic group (including Irish Travellers), migrant or refugee, living in a rural area, or experiencing socioeconomic disadvantage.
  • Living in Ireland
  • Able to give informed consent, with interpreter support if needed
  • Able to attend group sessions face to face or online

Exclusion Criteria:

  • Metastatic (stage IV) breast cancer
  • Severe mental health or cognitive difficulties that would prevent taking part in group sessions.
  • Currently taking part in another psychosocial intervention study
  • Took part in the BRIGHT co-design panel or user testing

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:支持治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:BRIGHT Resilience Intervention

Participants attend the 8-week culturally tailored BRIGHT resilience intervention: weekly 90-minute

A culturally tailored, co-designed group resilience programme for breast cancer survivors from underserved communities. Eight weekly 90-minute facilitated sessions, delivered in a hybrid format (community face to face and secure online). Planned modules: psychoeducation; emotional adjustment; managing fear of recurrence; culturally responsive coping and resilience; self-advocacy; healthcare navigation; peer support; and signposting to community resources. Delivered by trained facilitators using a standardised manual. Materials available in English and 2 to 3 priority languages.

有源比较器:Enhanced Usual Care

Participants receive standard oncology survivorship care plus the BRIGHT Survivorship Resource Booklet. They are offered the BRIGHT resilience intervention after the 3-month follow-up (waitlist crossover).

BRIGHT Survivorship Resource Booklet A printed resource booklet with survivorship information and signposting to support services, given alongside standard oncology survivorship care.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Recruitment Rate
大体时间:From start to end of recruitment, up to 6 months

Number of participants randomised per site per month. Progression target: at least 4 participants per site per month.

From start to end of recruitment, up to 6 months
Retention
大体时间:3 months after the end of the intervention

Percentage of randomised participants who complete the 3-month follow-up questionnaires. Progression target: at least 80%.

3 months after the end of the intervention
Session Attendance
大体时间:During the 8-week intervention

Percentage of the 8 intervention sessions attended by participants in the BRIGHT arm, from attendance records. Progression target: at least 75% session completion.

During the 8-week intervention
Intervention Fidelity
大体时间:During the 8-week intervention

Percentage of planned session components delivered as intended, assessed using facilitator session checklists and independent review of a sample of recorded sessions. Progression target: at least 85%.

During the 8-week intervention
Acceptability
大体时间:Week 8 (end of the intervention)

Participant satisfaction with the intervention, measured using a questionnaire based on the Theoretical Framework of Acceptability, and explored in interviews with 15 to 20 participants and facilitators.

Week 8 (end of the intervention)

次要结果测量

结果测量
措施说明
大体时间
Depressive Symptoms
大体时间:Baseline, Week 8 and 3 months after the end of the intervention

Patient Health Questionnaire-9 (PHQ-9). Scores range from 0 to 27; higher scores mean more severe depressive symptoms.

Baseline, Week 8 and 3 months after the end of the intervention
Anxiety Symptoms
大体时间:Baseline, Week 8 and 3 months after the end of the intervention

Generalised Anxiety Disorder-7 (GAD-7). Scores range from 0 to 21; higher scores mean more severe anxiety.

Baseline, Week 8 and 3 months after the end of the intervention
Fear of Cancer Recurrence
大体时间:Baseline, Week 8 and 3 months after the end of the intervention

Fear of Cancer Recurrence Inventory, Short Form (FCRI-SF). Scores range from 0 to 36; higher scores mean greater fear of recurrence.

Baseline, Week 8 and 3 months after the end of the intervention
Cancer-Specific Quality of Life
大体时间:Baseline, Week 8 and 3 months after the end of the intervention

Functional Assessment of Cancer Therapy, Breast (FACT-B). Total scores range from 0 to 148; higher scores mean better quality of life.

Baseline, Week 8 and 3 months after the end of the intervention
Psychological Resilience
大体时间:Baseline, Week 8 and 3 months after the end of the intervention

Connor-Davidson Resilience Scale (CD-RISC). Higher scores mean greater resilience

Baseline, Week 8 and 3 months after the end of the intervention
Unmet Supportive Care Needs
大体时间:Baseline, Week 8 and 3 months after the end of the intervention

Supportive Care Needs Survey, Short Form (SCNS-SF34). Domain scores range from 0 to 100; higher scores mean greater unmet need.

Baseline, Week 8 and 3 months after the end of the intervention

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2029年10月1日

初级完成 (估计的)

2030年9月1日

研究完成 (估计的)

2030年9月1日

研究注册日期

首次提交

2026年11月5日

首先提交符合 QC 标准的

2026年11月5日

首次发布 (实际的)

2026年11月12日

研究记录更新

最后更新发布 (实际的)

2026年11月12日

上次提交的符合 QC 标准的更新

2026年11月5日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

未定

IPD 计划说明

A decision on sharing anonymised individual participant data will be made before recruitment starts, in line with University College Dublin policy, funder requirements and GDPR.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅